IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 60,000 shares of its common stock. The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted pursuant to the Company’s 2026 Inducement Plan, with a grant date of October 1, 2026, as an inducement material to the new employee entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of such employee’s start date, with the remainder of the option vesting in 36 equal monthly installments thereafter, subject to continued employment on each vesting date.